クロストリジウム・ディフィシル感染症(クロストリジウム・ディフィシル関連疾患)(Clostridium Difficile Infections):世界の治験レビュー(2014年下半期版)

◆英語タイトル:Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Global Clinical Trials Review, H2, 2014
◆商品コード:GDHC2440CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2014年11月28日
◆ページ数:98
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥780,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるクロストリジウム・ディフィシル感染症(クロストリジウム・ディフィシル関連疾患)(Clostridium Difficile Infections) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - クロストリジウム・ディフィシル感染症(クロストリジウム・ディフィシル関連疾患)(Clostridium Difficile Infections)
  - 当レポートの概要
・クロストリジウム・ディフィシル感染症(クロストリジウム・ディフィシル関連疾患)(Clostridium Difficile Infections):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
【レポートの概要】

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Global Clinical Trials Review, H2, 2014

Summary

GlobalData’s clinical trial report, “Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Global Clinical Trials Review, H2, 2014″ provides data on the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Clostridium Difficile Infections (Clostridium Difficile Associated Disease). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Clostridium Difficile Infections (Clostridium Difficile Associated Disease). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 8
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) 8
Report Guidance 8
Clinical Trials by Region 9
Clinical Trials and Average Enrollment by Country 10
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) to Infectious Disease Clinical Trials 20
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Unaccomplished Trials of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) 27
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials 32
Prominent Drugs 34
Latest Clinical Trials News on Clostridium Difficile Infections (Clostridium Difficile Associated Disease) 35
Oct 24, 2014: Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 35
Oct 09, 2014: Study Shows Rebiotix Microbiota-based Drug Candidate Targeted at Recurrent C. difficile Infection is Highly Effective 35
Oct 08, 2014: Cubist to Present New Data from Study of fidaxomicin in Children with Clostridium Difficile-Associated Diarrhea at IDWeek 2014 36
Sep 17, 2014: PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 36
Sep 08, 2014: Seres Health Presents Final Data for Study of SER-109 in Recurrent Clostridium difficile Infection at ICAAC 2014 Conference 37
Sep 08, 2014: Summit Presents New Positive Preclinical Efficacy Data On Its Selective C Difficile Antibiotic SMT19969 At ICAAC 2014 38
Sep 07, 2014: Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC 38
Sep 02, 2014: Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 39
Clinical Trial Profiles 40
Clinical Trial Overview of Top Companies 40
Cubist Pharmaceuticals, Inc. 40
Clinical Trial Overview of Cubist Pharmaceuticals, Inc. 40
Sanofi 42
Clinical Trial Overview of Sanofi 42
Astellas Pharma Inc. 43
Clinical Trial Overview of Astellas Pharma Inc. 43
Synthetic Biologics, Inc. 44
Clinical Trial Overview of Synthetic Biologics, Inc. 44
Actelion Ltd 45
Clinical Trial Overview of Actelion Ltd 45
Pfizer Inc. 46
Clinical Trial Overview of Pfizer Inc. 46
Bio-K Plus International Inc. 47
Clinical Trial Overview of Bio-K Plus International Inc. 47
Romark Laboratories, L.C. 48
Clinical Trial Overview of Romark Laboratories, L.C. 48
Merck & Co., Inc. 49
Clinical Trial Overview of Merck & Co., Inc. 49
E. I. du Pont de Nemours and Company 50
Clinical Trial Overview of E. I. du Pont de Nemours and Company 50
Clinical Trial Overview of Top Institutes / Government 51
Hadassah Medical Organization 51
Clinical Trial Overview of Hadassah Medical Organization 51
John D. Dingell VA Medical Center 52
Clinical Trial Overview of John D. Dingell VA Medical Center 52
Massachusetts General Hospital 53
Clinical Trial Overview of Massachusetts General Hospital 53
University of Pittsburgh 54
Clinical Trial Overview of University of Pittsburgh 54
Columbia University 55
Clinical Trial Overview of Columbia University 55
Boston Medical Center 56
Clinical Trial Overview of Boston Medical Center 56
Spectrum Health System 57
Clinical Trial Overview of Spectrum Health System 57
University of Rochester 58
Clinical Trial Overview of University of Rochester 58
University of Arkansas 59
Clinical Trial Overview of University of Arkansas 59
Duke University 60
Clinical Trial Overview of Duke University 60
Five Key Clinical Profiles 61
Appendix 96
Abbreviations 96
Definitions 96
Research Methodology 97
Secondary Research 97
About GlobalData 98
Contact Us 98
Disclaimer 98
Source 98

List of Tables
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials by Region, 2014* 9
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 10
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 11
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 12
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 13
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, North America, Top Countries, 2014* 14
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 15
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 16
Proportion of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 17
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 18
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 19
Proportion of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 20
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 21
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 22
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials by Phase, 2014* 23
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 24
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 25
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 26
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Suspended Clinical Trials, 2014* 27
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 27
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 30
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cubist Pharmaceuticals, Inc., 2014* 40
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 42
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014* 43
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Synthetic Biologics, Inc., 2014* 44
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Actelion Ltd, 2014* 45
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 46
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bio-K Plus International Inc., 2014* 47
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Romark Laboratories, L.C., 2014* 48
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 49
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by E. I. du Pont de Nemours and Company, 2014* 50
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hadassah Medical Organization, 2014* 51
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by John D. Dingell VA Medical Center, 2014* 52
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 53
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 54
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2014* 55
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Boston Medical Center, 2014* 56
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Spectrum Health System, 2014* 57
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Rochester, 2014* 58
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Arkansas, 2014* 59
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 60

List of Figures
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials by Region (%), 2014* 9
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 10
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 11
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 12
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 13
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 14
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 15
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 16
Proportion of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 17
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 18
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 19
Proportion of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 20
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 21
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 22
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 23
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 24
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 25
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 26
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 30
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
GlobalData Methodology 97

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[クロストリジウム・ディフィシル感染症(クロストリジウム・ディフィシル関連疾患)(Clostridium Difficile Infections):世界の治験レビュー(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆